ExonHit Therapeutics was present at the PiperJaffray healthcare
conference in London giving investors updates on company activity
over the last year. The company are coming off the back of a patent
application, which covers a number...
DanioLabs has announced the start of a Phase I proof-of-concept
trial of DL06001 and DL06002 for sialorrhoea (drooling) and
hyperhidrosis (excessive sweating) in Parkinson's disease as the
company aim to meet the need for treating...
Researchers have constructed a model of an axon, which they have
used to reproduce a change in the axon's shape that is
characteristic of neurodegenerative disorders. The model provides a
new road to discovering new kinds of...
New drugs that are based on a compound found in the body may give
renewed hope to stroke victims and sufferers of degenerative brain
diseases such as Alzheimer's as researchers are hopeful of a new
therapeutic approach.
A clinical trial will shortly get underway to see if insulin,
delivered intranasally using an atomiser developed by Kurve
Technology, can improve short-term memory in Alzheimer's disease
patients.
Ablynx has announced that it had signed a collaborative agreement
with the National Research Council of Canada (NRC) Institute for
Biological Sciences (IBS) that aims to concentrate its discovery
efforts in the area of neurodegenerative...
Newron Pharmaceuticals has announced the company and a consortium
will use the money raised from European funding to utilise
drug-screening technology for the HTS of molecules for ion channel
targets for neurological and psychiatric...
German, US and Canadian researchers have discovered a gene and six
mutations that cause symptoms associated with Parkinson's disease
and other neurodegenerative disorders.
A whole new generation of drug treatments and therapies for stroke,
migraine, Alzheimer's and other brain disorders could be created
after the discovery of a mechanism for regulating brain blood flow
was made by researchers.